

Special Issue

Novel Biomarkers of Neurodegenerative Diseases

Message from the Guest Editor

Neurodegenerative diseases represent one of the most pressing medical challenges of our time, affecting millions worldwide and imposing enormous burdens on patients, families, and healthcare systems. Central to addressing these challenges is the identification and validation of genetic biomarkers that can transform our approach to neurodegenerative disease management through precision medicine approaches.

This Special Issue aims to showcase cutting-edge research in the discovery, development, and clinical application of genetic biomarkers for neurodegenerative diseases, with a particular focus on those enabling earlier diagnosis, differential diagnosis, risk stratification, and the monitoring of disease progression.

Of particular interest are studies that demonstrate translational potential. We also welcome research on gene–environment interactions, genetic modifiers of disease penetrance and progression, and novel computational approaches for genetic biomarker discovery and validation in neurodegenerative diseases.

Guest Editor

Dr. Arash Salardini

Division of Cognitive and Behavioral Therapy Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA

Deadline for manuscript submissions

closed (1 April 2026)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/245821

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))